Proliferating-cell nuclear antigen (PC10) immunolabelling and other proliferation indices as prognostic factors in breast cancer
| Autor: | Sirpa Aaltomaa, Pertti Lipponen, Kari Syrjänen, Papinaho S |
|---|---|
| Rok vydání: | 1993 |
| Předmět: |
Adult
Cancer Research Pathology medicine.medical_specialty Mitotic index Mammary gland Breast Neoplasms Biology Epithelium S Phase Andrology Breast cancer Antigens Neoplasm Proliferating Cell Nuclear Antigen medicine Carcinoma Biomarkers Tumor Humans Aged Aged 80 and over Univariate analysis Ploidies Epithelioma Nuclear Proteins General Medicine DNA Neoplasm Middle Aged medicine.disease Prognosis Immunohistochemistry Survival Analysis Proliferating cell nuclear antigen medicine.anatomical_structure Oncology Multivariate Analysis biology.protein Female Cell Division Follow-Up Studies |
| Zdroj: | Journal of cancer research and clinical oncology. 119(5) |
| ISSN: | 0171-5216 |
| Popis: | Proliferating cell nuclear antigen, PCNA (PC10), immunolabelling was determined in 175 women with breast carcinomas and related to other established prognostic factors: flow-cytometric data, volume-corrected mitotic index, sex steroid receptor content and clinical outcome during the mean follow-up of 9 years. The maximum fraction of PCNA-positive nuclei (PCNAmax), the average fraction of positive nuclei (PCNAtot) and the number of intensely stained nuclei per microscope field (PCNAcount) were significantly related to histological grade (P0.001), DNA ploidy ((P0.001), S-phase fraction (P0.001), mitotic index (P0.001) and sex steroid receptor content (P = 0.002). PCNAmax (P = 0.015) predicted survival in univariate analysis; PCNAtot (P = 0.025), PCNAmax (P = 0.007) and PCNAcount (P = 0.019) predicted the recurrence-free survival. In axillary-lymph-node-negative tumours, PCNAtot (P = 0.092), PCNAmax (P = 0.036) and PCNAcount (P = 0.006) predicted survival and recurrence-free survival (P = 0.011), (P = 0.012) and (P = 0.006) respectively. In multivariate analysis including clinical, histological, flow-cytometric and biochemical variables, PCNAtot (P = 0.004) predicted the recurrence-free survival independently. In axillary-lymph-node-negative breast cancers, PCNAtot predicted accurately the patient survival (P = 0.002) and the recurrence-free survival (P = 0.002). The results indicate that PCNA immunolabelling has independent prognostic value particularly in local breast cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink